Αποτελέσματα Αναζήτησης
11 Ιουν 2020 · Very cost-effective interventions, based on supportive evidence, were both new findings in this updated review: 1) statin treatment at T2D diagnosis compared with no lipid-regulating treatment ($3,294/QALY) and 2) bariatric surgery for individuals with T2D and overweight compared with no surgery ($23,320/QALY).
27 Μαρ 2024 · This economic evaluation study estimated the cost of production for insulins, SGLT2Is, and GLP1As, and, based on this, a sustainable cost-based price (CBP), and compared CBPs with the current lowest reported prices in 12 countries, collected in January 2023 from public databases.
21 Ιουν 2019 · To report Type 1.5 diabetes mellitus, coders should assign ICD-10-CM codes from category E13.- (other specified diabetes mellitus). In this case, the provider specifically documented “combination Type 1 and 2 diabetes mellitus in poor control”; therefore, the coder should assign code E13.65 (other specified diabetes mellitus with ...
We classified the interventions based on their strength of evidence (strong, supportive, or uncertain) and levels of CE: cost-saving (more health benefit at a lower cost), very cost-effective (≤$25,000 per life year gained [LYG] or quality-adjusted life year [QALY]), cost-effective ($25,001-$50,000 per LYG or QALY), marginally cost-effective ...
15 Ιαν 2018 · The cost of diabetes continues to increase, reflecting growing disease prevalence and cost of treatment. . This study was based on real-world claims data for patients with type 1 or type 2 diabetes in the United States, using 2 cost-estimation methods. .
Treatment cascade for people with diabetes, from the WHO STEPwise approach to Surveillance and attendant surveys (2006–18) 15 Diagnosis rate with diabetes mellitus is defined as the proportion of those reporting a previous diagnosis of diabetes, among those with clinical diabetes (defined as fasting blood glucose >7 mmol/L, or non-fasting blood glucose >11·1 mmol/L, HbA 1c ≥6·5% [48 mmol ...
29 Ιουλ 2023 · This systematic review aimed to compare the cost-effectiveness of newer antidiabetic drugs specified as sodium-glucose cotransporter 2 inhibitor (SGLT2i), glucagon-like peptide 1 receptor agonist (GLP-1RA), and dipeptidyl peptidase 4 inhibitor (DPP-4i) for T2D in a second-line setting.
